Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
SELECT, Semaglutide, & the Future of Incretin Therapies, with A. Michael Lincoff, MD
02 Mar 2024
In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies. Chapters: 00:35 - Guest Introduction 01:10 - SELECT Results Overview 04:25 - Next Steps for Research 07:15 - Mechanism of Action for CV Benefit 09:00 - FLOW Trial Implications 11:25 - Impact on Access 15:00 - Future of Incretin Therapies 21:45 - Predicting the Next 5-10 Years for Semaglutide
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana